跳至主要内容
临床试验/NCT06223854
NCT06223854已完成不适用

Evaluation of the Acceptability and Nutritional Effects of Double-fortified Salt Containing Folic Acid and Iodine Among Ethiopian Women of Reproductive Age - a Household-randomized, Controlled, Community-based Trial

University of California, Davis1 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2024年4月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
360
试验地点
1
主要终点
Serious adverse events

研究概览

简要总结

The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status. Folate insufficiency is the primary risk factor for neural tube defects (NTDs), which are highly prevalent in Ethiopia. The purposes of Phase 2 of the project, described herein, are to complete a community-based, randomized, dose-response intervention trial of edible salt fortified with just iodine or iodine and one of two levels of folic acid among non-pregnant women of reproductive age (WRA), We will assess the effects of the intervention on women's discretionary salt intakes, markers of folate and iodine status, and incidence of any adverse events.

详细描述

Potentially eligible women of reproductive age (WRA) in two rural and two semi-urban communities (kebeles) in the Oromia Region of Ethiopia will be identified from existing census records. A convenience sample of 360 eligible, consenting women will be recruited following an initial screening interview at the women's homes. Before the screening interview, the data collector will read a disclosure statement concerning the purpose and the contents of the interview, and the data collector will then request verbal consent to obtain descriptive information on the women's age, general health status, pregnancy status, use of contraceptives, address, cell phone number (if available), and potential willingness to participate in the subsequent intervention trial.

After reviewing the women's health history and pregnancy status, measured blood pressure, and current use of contraceptives, the data collector will determine the women's potential eligibility for the trial. The data collector will describe the purposes of the trial, the study procedures and related risks and benefits, the confidentiality of results, and the fact that participation is voluntary. Women who are interested in participating in the study will be encouraged to ask any questions to the research team and consult with family members before providing their signed consent (in the presence of a neutral witness) to participate in the trial. Additional questions then will be asked of consenting women regarding their marital status, ethnicity, religion, educational level, and employment; and their housing characteristics (housing construction, water source, sanitary facilities, access to electricity and cell phone service), and selected household (HH) assets; and the women will be invited to attend the local health facility to complete additional interviews to assess their birth history, household food insecurity, and additional eligibility criteria, including anthropometrics, a pregnancy test, and fasting blood collection for anemia screening and other baseline measurements. Eligible, consenting women then will be randomly assigned to one of three study arms using a block randomization procedure with block size of six. The fasting blood samples obtained for anemia screening will also be used for measurement of red blood cell and serum folate, unmetabolized folic acid, homocysteine, vitamin B12, holo-transcobalamin, methyl malonic acid, other B vitamins, genetic polymorphisms that affect folate metabolism, thyroglobulin, glucose, insulin, retinol binding protein (RBP), ferritin, soluble transferrin receptor, C-reactive protein, and alpha-1 acid glycoprotein, and a malaria rapid diagnostic test (RDT).

Following enrollment, the study participants will be scheduled for a 24-hour urine collection to measure baseline sodium and iodine excretion, after which they will begin receiving the assigned study salt every two weeks. The women will be counseled to use the study salt for all food preparation and seasoning for a total of 26 weeks. Additional data collection during the course of the intervention will include: one or two full-day observed food records to measure discretionary salt intake and folate intake; one or two repeat 24-hour urine collections to measure sodium and iodine excretion; and bi-weekly home assessments of salt acceptability, continued contraceptive use, and any adverse events. At the time of these bi-weekly home visits, unused salt will be collected and a new allotment of salt will be delivered. Fasting blood samples will be collected again at a randomly assigned intermediate time point and at end line.

  • Page 2 of 5 -

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The salts will be packaged in 500-gram plastic containers (canisters) labeled with the participants' study identification number. Two containers of salt will be delivered to the participants' homes every two weeks, at which time the previously delivered canisters will be collected..

入排标准

年龄范围
18 Years 至 49 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Non-pregnant
  • Using long-acting contraceptive
  • Intending to remain in study community for at least six months
  • Willing to use study salt for all household food preparation and seasoning
  • Signed, informed consent

排除标准

  • Not using long-acting contraceptive
  • Acute or chronic disease that affects dietary intake or folate metabolism
  • Hypertension
  • Medications that potentially interfere with folate metabolism
  • Folic acid-containing vitamin supplements
  • Macrocytic anemia or moderate/severe non-macrocytic anemia.
  • Mid-upper arm circumference <23 cm and breast feeding an infant <6 months of age

结局指标

主要结局

Serious adverse events

时间窗: Throughout the course of the intervention, total of 26 weeks

Serious adverse events requiring an overnight stay in a clinical facility or resulting in disability, or death will be recorded during each bi-weekly home visit.

Red blood cell folate

时间窗: Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks)

Red blood cell (RBC) folate concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention. RBC folate concentration will be will be determined by using a microbiological assay.

Serum folate

时间窗: Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks)

Serum folate concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention, by using a microbiological assay.

24-hour urinary iodine excretion

时间窗: Before and during the intervention

24-hour urinary iodine excretion will be measured prior to the start of the intervention and at a second time time at least 4 weeks after the start of the intervention.

Serum homocysteine

时间窗: Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks)

Serum homocysteine concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention.

Serum thyroglobulin

时间窗: Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks)

Serum thyroglobulin concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention.

次要结局

  • Hemoglobin concentration(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Serum insulin(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Serum methyl malonic acid(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Urinary sodium excretion(Before and between 4-20 weeks after the start of the intervention)
  • Serum B12(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Discretionary salt intake(After the start of the intervention, between 4-20 weeks)
  • Serum unmetabolized folic acid(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Serum glucose(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))
  • Serum transcobalamin(Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验